Biomerica shares rise 18% premarket after Egyptian Drug Authority authorizes full cancer screening test portfolio for Egypt.

Biomerica (NASDAQ: BMRA) surged 18% in premarket trading following the Egyptian Drug Authority’s authorization of its complete portfolio of rapid diagnostic tests for cancer and chronic disease detection. The approval covers at-home and point-of-care tests for colorectal, breast, prostate, kidney, and H. pylori-related conditions, offering quick, cost-effective screening solutions in a region with significant unmet healthcare needs. The authorization, described as a "milestone" by the CEO, expands Biomerica’s presence in the Middle East and North Africa, aligning with its strategy to provide accessible diagnostic tools for early disease detection. The news underscores potential revenue growth in a high-prevalence market, with colorectal and breast cancers being major health concerns in Egypt. The regulatory clearance strengthens the company’s position in global preventive healthcare and supports large-scale screening initiatives.